Literature DB >> 17644187

Flow cytometric analysis on cross-reactivity of human-specific CD monoclonal antibodies with splenocytes of Aotus nancymaae, a non-human primate model for biomedical research.

Claudia A Daubenberger1, Rolf Spirig, Manuel E Patarroyo, Gerd Pluschke.   

Abstract

The reactivity of 204 monoclonal antibodies (mAb) out of 377 commercially available antibodies collected by the animal homologue group of the HLAD8 was analyzed by single colour flow cytometry. Most of these mAb were originally developed against human cell surface molecules. Fifty-eight mAb (28%) showed reactivity with spleen cells of Aotus nancymaae, a non-human primate animal model in biomedical research. Out of these 58 mAb, 22 also showed reactivity with mononuclear cells derived from rhesus macaques and cynomolgus monkeys indicating that the epitopes recognized are evolutionary conserved between human, Old and New World monkeys. This novel panel of A. nancymaae reactive mAb will increase the potential to explore complex host-pathogen interactions in non-human primate animal models, particularly in malaria vaccine research.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17644187     DOI: 10.1016/j.vetimm.2007.06.010

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  2 in total

1.  Distinctive Leukocyte Subpopulations According to Organ Type in Cynomolgus Macaques.

Authors:  Jonah S Zitsman; Paula Alonso-Guallart; Christopher Ovanez; Yojiro Kato; Joanna F Rosen; Joshua I Weiner; Raimon Duran-Struuck
Journal:  Comp Med       Date:  2016       Impact factor: 0.982

2.  Molecular and immunological tools for the evaluation of the cellular immune response in the neotropical monkey Saimiri sciureus, a non-human primate model for malaria research.

Authors:  Evelyn K P Riccio; Lilian R Pratt-Riccio; Cesare Bianco-Júnior; Violette Sanchez; Paulo R R Totino; Leonardo J M Carvalho; Cláudio Tadeu Daniel-Ribeiro
Journal:  Malar J       Date:  2015-04-18       Impact factor: 2.979

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.